Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocytes.

Gu C, Zhou G, Noble NA, Border WA, Cheung AK, Huang Y.

J Renin Angiotensin Aldosterone Syst. 2014 Jun;15(2):177-89. doi: 10.1177/1470320312466127. Epub 2012 Dec 4.

PMID:
23223090
2.

Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.

Zhou G, Cheung AK, Liu X, Huang Y.

Clin Sci (Lond). 2014 May;126(10):707-20. doi: 10.1042/CS20130223.

PMID:
24195695
3.

Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis.

Mahmood J, Khan F, Okada S, Kumagai N, Morioka T, Oite T.

Kidney Int. 2006 Nov;70(9):1591-8. Epub 2006 Sep 20.

4.

Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.

Zhang Y, Chen B, Hou XH, Guan GJ, Liu G, Liu HY, Li XG.

Chin Med J (Engl). 2007 Jun 5;120(11):988-95.

PMID:
17624267
5.

Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.

Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, Kishida M, Hamada M, Nagai Y, Nakagawa T, Ohashi N, Nakano D, Hitomi H, Imanishi M.

J Pharmacol Exp Ther. 2010 Mar;332(3):1072-80. doi: 10.1124/jpet.109.158113. Epub 2009 Nov 25.

6.

[Effects of benazepril and valsartan alone or in combination on proteinuria in chronic glomerular disease].

Zhang DY, Yang YL, Chen WD, Huang YY, Li LH, Wang YW, Zhu XJ, Xu HH, Yang LC.

Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007 Dec;19(12):762-3. Chinese. No abstract available.

7.

Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.

Esnault VL, Ekhlas A, Nguyen JM, Moranne O.

Nephrol Dial Transplant. 2010 Jul;25(7):2218-24. doi: 10.1093/ndt/gfp776. Epub 2010 Jan 26.

PMID:
20106824
8.

[Molecular mechanisms underlying proteinuria reduction and protection of nephrin and podocytes by ARB].

Kumagai H, Onami T, Takimoto C, Iigaya K, Saruta T.

Nihon Rinsho. 2006 Feb;64 Suppl 2:639-46. Review. Japanese. No abstract available.

PMID:
16523969
9.

Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.

Tominaga N, Robert A, Izuhara Y, Ohtomo S, Dan T, Chihara K, Kurokawa K, Van Ypersele de Strihou C, Miyata T.

Nephrology (Carlton). 2009 Sep;14(6):581-7. doi: 10.1111/j.1440-1797.2009.01143.x.

PMID:
19712258
10.

Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.

Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5.

11.

Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.

Naito T, Ma LJ, Yang H, Zuo Y, Tang Y, Han JY, Kon V, Fogo AB.

Am J Physiol Renal Physiol. 2010 Mar;298(3):F683-91. doi: 10.1152/ajprenal.00503.2009. Epub 2009 Dec 30.

12.

Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria.

Hayashi K, Sasamura H, Nakamura M, Sakamaki Y, Azegami T, Oguchi H, Tokuyama H, Wakino S, Hayashi K, Itoh H.

Kidney Int. 2015 Oct;88(4):745-53. doi: 10.1038/ki.2015.178. Epub 2015 Jun 24.

PMID:
26108068
13.

Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.

Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G.

Am J Physiol Renal Physiol. 2010 Nov;299(5):F1203-11. doi: 10.1152/ajprenal.00045.2010. Epub 2010 Aug 18.

14.

Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis.

Zhang J, Noble NA, Border WA, Huang Y.

Am J Physiol Renal Physiol. 2010 Mar;298(3):F579-88. doi: 10.1152/ajprenal.00548.2009. Epub 2009 Dec 23.

15.

Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.

Whaley-Connell A, Habibi J, Nistala R, Hayden MR, Pulakat L, Sinak C, Locher B, Ferrario CM, Sowers JR.

Regul Pept. 2012 Jun 10;176(1-3):36-44. doi: 10.1016/j.regpep.2012.03.002. Epub 2012 Mar 29.

16.

Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.

Wang W, Qiu L, Howard A, Solis N, Li C, Wang X, Kopp JB, Levi M.

J Renin Angiotensin Aldosterone Syst. 2014 Dec;15(4):384-95. doi: 10.1177/1470320313507123. Epub 2014 Jul 16.

PMID:
25031296
17.

Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect.

Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA.

Kidney Int. 2004 Nov;66(5):1774-84.

18.

Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall.

Sironi L, Gelosa P, Guerrini U, Banfi C, Crippa V, Brioschi M, Gianazza E, Nobili E, Gianella A, de Gasparo M, Tremoli E.

J Pharmacol Exp Ther. 2004 Dec;311(3):989-95. Epub 2004 Aug 9.

19.

Angiotensin II type 1 receptor blockade inhibits the development and progression of HIV-associated nephropathy in a mouse model.

Hiramatsu N, Hiromura K, Shigehara T, Kuroiwa T, Ideura H, Sakurai N, Takeuchi S, Tomioka M, Ikeuchi H, Kaneko Y, Ueki K, Kopp JB, Nojima Y.

J Am Soc Nephrol. 2007 Feb;18(2):515-27. Epub 2007 Jan 17.

20.

Multi-glycoside of Tripterygium wilfordii Hook. f. reduces proteinuria through improving podocyte slit diaphragm dysfunction in anti-Thy1.1 glomerulonephritis.

Wan YG, Sun W, Zhen YJ, Che XY, Pu HP, Wang Y, Li M, Ruan JG, Yan QJ.

J Ethnopharmacol. 2011 Jun 22;136(2):322-33. doi: 10.1016/j.jep.2011.04.046. Epub 2011 May 6.

PMID:
21570456

Supplemental Content

Support Center